Skip to content

The AMD Experts

50196296_795957517416981_458178117475762176_n

Our Team

The MacuLogix team is committed to empowering primary eye care professionals with the technology and tools needed to create AMD Centers of Excellence®.

Bill McPhee, the President and CEO of MacuLogix, shares his personal story of why he joined the company and adopted its vision of eliminating blindness caused by AMD.

The AdaptDx is especially useful for optometrists and general ophthalmologists who see many patients with “normal” clinical exams, since it can detect subclinical AMD up to three years before clinical onset. With the AdaptDx, you will be in the front line in detecting these patients and will be able to carefully monitor and treat those with subclinical AMD.

Dr. Shawn Lewis1 Shawn Lewis, MD View all testimonials

Latest News & Upcoming Events

View More
Article: June 15, 2019 | Review of Optometry

How to Stay One Step Ahead of AMD

Optometrists can truly stay ahead of AMD if they change the way they approach it, by identifying disease risk during routine examinations and by using dark adaptation testing for early detection.

Article: June 12, 2019 | Review of Optometric Business

The 3 Instruments that Delivered the Best ROI for My Practice

The AdaptDx enables Dr. Hammond to test patients’ dark adaption time, providing info that could indicate subclinical AMD. The practice can then start early treatment to improve patient outcomes.

Blog: May 14, 2019

Hey Doc, Why Am I Having Problems Seeing at Night?

"When you think about night vision, think of AMD." By Timothy Earley, OD.

Put Our Expertise to Work

Testing with AdaptDx

AdaptDx identifies impaired dark adaptation—the earliest warning sign of AMD.

Guiding AdaptDx Implementation

Each AdaptDx purchase is supported by our AMD Excellence Program™ to help you achieve your patient care and practice revenue goals.